Arne Ittner

2.7k total citations
36 papers, 1.9k citations indexed

About

Arne Ittner is a scholar working on Physiology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Arne Ittner has authored 36 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Physiology, 19 papers in Cellular and Molecular Neuroscience and 15 papers in Molecular Biology. Recurrent topics in Arne Ittner's work include Alzheimer's disease research and treatments (27 papers), Neuroscience and Neuropharmacology Research (19 papers) and Cholinesterase and Neurodegenerative Diseases (9 papers). Arne Ittner is often cited by papers focused on Alzheimer's disease research and treatments (27 papers), Neuroscience and Neuropharmacology Research (19 papers) and Cholinesterase and Neurodegenerative Diseases (9 papers). Arne Ittner collaborates with scholars based in Australia, United Kingdom and Switzerland. Arne Ittner's co-authors include Lars M. Ittner, Jürgen Götz, Yazi D. Ke, Helmuth Gehart, Roméo Ricci, Josefine Bertz, Kristie Stefanoska, Janet van Eersel, Mian Bi and Prita R. Asih and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Neuron.

In The Last Decade

Arne Ittner

36 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arne Ittner Australia 23 1.0k 748 535 388 291 36 1.9k
Herman Devijver Belgium 22 1.0k 1.0× 957 1.3× 606 1.1× 346 0.9× 340 1.2× 31 2.0k
Katherine J. Kopeikina United States 14 916 0.9× 506 0.7× 560 1.0× 329 0.8× 196 0.7× 15 1.5k
Shu-Ming Huang China 10 1.5k 1.5× 677 0.9× 696 1.3× 790 2.0× 310 1.1× 22 2.2k
Amadeus Gladbach Australia 12 1.5k 1.5× 739 1.0× 848 1.6× 504 1.3× 372 1.3× 13 2.3k
Kunié Ando Belgium 25 1.1k 1.1× 869 1.2× 512 1.0× 394 1.0× 229 0.8× 57 1.8k
Ian A. Napier Australia 10 1.3k 1.2× 771 1.0× 897 1.7× 330 0.9× 430 1.5× 10 2.0k
Kengo Uemura Japan 31 979 1.0× 911 1.2× 559 1.0× 329 0.8× 254 0.9× 58 2.1k
Estibaliz Capetillo‐Zarate Spain 26 1.4k 1.4× 791 1.1× 797 1.5× 784 2.0× 321 1.1× 44 2.6k
Mian Bi Australia 11 1.6k 1.6× 758 1.0× 866 1.6× 529 1.4× 398 1.4× 16 2.2k
Jennifer Paulson United States 7 1.7k 1.7× 711 1.0× 895 1.7× 597 1.5× 375 1.3× 8 2.3k

Countries citing papers authored by Arne Ittner

Since Specialization
Citations

This map shows the geographic impact of Arne Ittner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arne Ittner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arne Ittner more than expected).

Fields of papers citing papers by Arne Ittner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arne Ittner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arne Ittner. The network helps show where Arne Ittner may publish in the future.

Co-authorship network of co-authors of Arne Ittner

This figure shows the co-authorship network connecting the top 25 collaborators of Arne Ittner. A scholar is included among the top collaborators of Arne Ittner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arne Ittner. Arne Ittner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jacobs, Kelly R., Paul Maruff, Alan Rembach, et al.. (2022). Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β. Neurobiology of Disease. 171. 105783–105783. 11 indexed citations
2.
3.
Ittner, Arne, Prita R. Asih, Josefine Bertz, et al.. (2020). Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ. Acta Neuropathologica. 140(3). 279–294. 26 indexed citations
4.
Watt, Georgia, et al.. (2020). The behavioural phenotype of 14-month-old female TAU58/2 transgenic mice. Behavioural Brain Research. 397. 112943–112943. 4 indexed citations
5.
Asih, Prita R., et al.. (2020). Functions of p38 MAP Kinases in the Central Nervous System. Frontiers in Molecular Neuroscience. 13. 570586–570586. 114 indexed citations
6.
Watt, Georgia, Rose Chesworth, Magdalena Przybyla, et al.. (2020). Chronic cannabidiol (CBD) treatment did not exhibit beneficial effects in 4-month-old male TAU58/2 transgenic mice. Pharmacology Biochemistry and Behavior. 196. 172970–172970. 17 indexed citations
7.
Watt, Georgia, Magdalena Przybyla, Janet van Eersel, et al.. (2020). Novel Behavioural Characteristics of Male Human P301S Mutant Tau Transgenic Mice – A Model for Tauopathy. Neuroscience. 431. 166–175. 16 indexed citations
8.
Teo, Jonathan D., Holly P. McEwen, Jun Yup Lee, et al.. (2019). Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience. 39(48). 9645–9659. 23 indexed citations
9.
Ke, Yazi D., Kristie Stefanoska, Carol G. Au, et al.. (2019). CNS cell type–specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. Journal of Biological Chemistry. 294(38). 14149–14162. 10 indexed citations
10.
Ittner, Arne, et al.. (2018). Generation of a New Tau Knockout (tauΔex1) Line Using CRISPR/Cas9 Genome Editing in Mice. Journal of Alzheimer s Disease. 62(2). 571–578. 30 indexed citations
11.
Stefanoska, Kristie, Josefine Bertz, Alexander Volkerling, et al.. (2018). Neuronal MAP kinase p38α inhibits c-Jun N-terminal kinase to modulate anxiety-related behaviour. Scientific Reports. 8(1). 14296–14296. 29 indexed citations
12.
Stefanoska, Kristie, Alexander Volkerling, Josefine Bertz, et al.. (2018). An N-terminal motif unique to primate tau enables differential protein–protein interactions. Journal of Biological Chemistry. 293(10). 3710–3719. 50 indexed citations
13.
Bi, Mian, Amadeus Gladbach, Janet van Eersel, et al.. (2017). Tau exacerbates excitotoxic brain damage in an animal model of stroke. Nature Communications. 8(1). 473–473. 133 indexed citations
14.
Ahmed, Rebekah M., Muireann Irish, Janet van Eersel, et al.. (2017). Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. Neuroscience & Biobehavioral Reviews. 74(Pt A). 126–138. 28 indexed citations
15.
Ahmed, Rebekah M., Emma Devenney, Muireann Irish, et al.. (2016). Neuronal network disintegration: common pathways linking neurodegenerative diseases. Journal of Neurology Neurosurgery & Psychiatry. 87(11). 1234–1241. 93 indexed citations
16.
Przybyla, Magdalena, Claire H. Stevens, Julia van der Hoven, et al.. (2016). Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia. Neuroscience Letters. 631. 24–29. 31 indexed citations
17.
Ittner, Arne, et al.. (2014). p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimer’s disease. Acta Neuropathologica Communications. 2(1). 149–149. 62 indexed citations
18.
Attems, Johannes, Arne Ittner, K. A. Jellinger, et al.. (2011). Reduced secretagogin expression in the hippocampus of P301L tau transgenic mice. Journal of Neural Transmission. 118(5). 737–745. 19 indexed citations
19.
Bi, Mian, Arne Ittner, Yazi D. Ke, Jürgen Götz, & Lars M. Ittner. (2011). Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice. PLoS ONE. 6(12). e26860–e26860. 129 indexed citations
20.
Götz, Jürgen, Arne Ittner, & Lars M. Ittner. (2011). Tau‐targeted treatment strategies in Alzheimer's disease. British Journal of Pharmacology. 165(5). 1246–1259. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Herman Devijver Breakdown of academic impact, for papers by Katherine J. Kopeikina Breakdown of academic impact, for papers by Shu-Ming Huang Breakdown of academic impact, for papers by Amadeus Gladbach Breakdown of academic impact, for papers by Kunié Ando Breakdown of academic impact, for papers by Ian A. Napier Breakdown of academic impact, for papers by Kengo Uemura Breakdown of academic impact, for papers by Estibaliz Capetillo‐Zarate Breakdown of academic impact, for papers by Mian Bi Breakdown of academic impact, for papers by Jennifer Paulson
Rankless by CCL
2026